A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results.
Medical Xpress – latest medical and health news stories